admin – Page 2434 – Get News Story

Acute Agitation and Aggression Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Acute Agitation and Aggression Market”

Acute Agitation and Aggression companies are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.

(Albany, USA) DelveInsight’s report, “Acute Agitation and Aggression Market Insights, Epidemiology, and Market Forecast–2034”, offers a comprehensive analysis of Acute Agitation and Aggression, including historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report examines current treatment practices, emerging therapies, market share by individual drugs, and the Acute Agitation and Aggression market size from 2020 to 2034, segmented across the seven major markets. It also outlines existing treatment algorithms, key market drivers and barriers, and prevailing unmet medical needs, aiming to identify the most promising opportunities. Furthermore, it evaluates the overall market potential, providing valuable insights for stakeholders to understand the evolving treatment landscape and growth prospects in Acute Agitation and Aggression management.

Request for a Free Sample Report @ Acute Agitation and Aggression Market Forecast

Some facts of the Acute Agitation and Aggression Market Report are:

According to DelveInsight, Acute Agitation and Aggression market size is expected to grow at a decent CAGR by 2034.
Leading Acute Agitation and Aggression companies working in the market are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.
Key Acute Agitation and Aggression Therapies expected to launch in the market are IGALMI (dexmedetomidine), REXULTI (brexpiprazole), AUVELITY (dextromethorphan-bupropion; AXS-05), Masupirdine (SUVN-502), ITI-1284, and many others.
In April 2025, Suven Life Sciences presented updated clinical data and outlined development plans for masupirdine’s Phase III program at the American Academy of Neurology (AAN) Annual Meeting.
In December 2024, Axsome announced the successful completion of its Phase III clinical program for AXS-05, which included the ADVANCE-1 Phase II/III trial, the ADVANCE-2, ACCORD-1, and ACCORD-2 Phase III trials, as well as an open-label extension study assessing long-term safety and efficacy.
According to the secondary search, acute agitation accounted for 4.6% of psychiatric emergencies in Europe.
Across Germany, Spain, and the UK, agitation was reported in 55% of patients with schizophrenia and 66% of those with bipolar disorder.
In Germany, Spain, and the UK, common symptoms reported during agitation episodes included feeling uneasy 64%, restless 63%, and nervous 63%, along with other symptoms such as feeling tense and being unable to sit still.

Acute Agitation and Aggression Overview

Acute agitation and aggression are behavioral states characterized by excessive motor activity, heightened arousal, and an increased potential for harmful actions toward oneself or others. They can occur suddenly and are often associated with psychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, or dementia, as well as neurological disorders, substance intoxication or withdrawal, and certain medical conditions. Acute agitation typically manifests as restlessness, irritability, excessive talking, pacing, clenched fists, or heightened emotional tension, while aggression involves overt verbal or physical hostility.

These episodes may be triggered by underlying mental health conditions, environmental stressors, pain, fear, or unmet needs. If left unmanaged, they can escalate quickly, posing safety risks to patients, caregivers, and healthcare providers. Diagnosis involves assessing the severity, underlying cause, and potential risk factors through patient history, observation, and clinical evaluation.

Management focuses on rapid de-escalation to ensure safety. Non-pharmacological approaches include verbal de-escalation, environmental modification, and behavioral interventions. Pharmacological treatment may involve antipsychotics, benzodiazepines, or mood stabilizers, chosen based on the underlying cause and patient profile. Early recognition and timely intervention are crucial to prevent harm and improve outcomes, with ongoing care aimed at addressing the root cause and reducing recurrence.

Do you know what will be the Acute Agitation and Aggression market share in 7MM by 2034 @ Acute Agitation and Aggression Market Outlook

Acute Agitation and Aggression Market

The acute agitation and aggression market is expected to grow steadily from 2025–2034, driven by rising psychiatric disorder prevalence, aging populations, substance use, and cognitive decline. Current treatments include IGALMI, offering rapid sublingual relief for schizophrenia- and bipolar-related episodes, and REXULTI, approved for Alzheimer’s-related agitation, highlighting label expansion into neurodegenerative conditions. However, no single therapy yet provides both fast onset and sustained control across psychiatric, neurodegenerative, and pediatric cases with minimal side effects. Emerging candidates like AUVELITY, masupirdine, and ITI-1284 are in development, and their anticipated approvals are likely to intensify competition, accelerating market growth and expanding treatment options.

The acute agitation and aggression market is driven by the rising prevalence of psychiatric and neurodegenerative disorders, increasing substance use, aging populations, and advancements in rapid-acting therapeutic options. Growing R&D investments and novel drug approvals, such as IGALMI and REXULTI, are expanding treatment choices and addressing unmet needs. However, market growth is hindered by the absence of a single therapy offering both rapid and sustained symptom control across diverse patient groups, limited long-term safety data, and challenges in pediatric treatment. Additionally, regulatory hurdles, side-effect profiles, and the complexity of conducting large-scale trials in acute behavioral emergencies remain significant barriers.

According to DelveInsight, the Acute Agitation and Aggression market in 7MM is expected to witness a major change in the study period 2020-2034.

Acute Agitation and Aggression Epidemiology

The Acute Agitation and Aggression epidemiology section provides insights into the historical and current Acute Agitation and Aggression patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Agitation and Aggression market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total Prevalent Cases Of Acute Agitation and Aggression
Total Diagnosed Prevalent Cases Of Acute Agitation and Aggression
Comorbidities-associated Cases of Acute Agitation and Aggression
Symptom-specific Cases of Acute Agitation and Aggression
Treated Cases of Acute Agitation and Aggression

Some of the facts:

According to the secondary search, acute agitation accounted for 4.6% of psychiatric emergencies in Europe.
Across Germany, Spain, and the UK, agitation was reported in 55% of patients with schizophrenia and 66% of those with bipolar disorder.
In Germany, Spain, and the UK, common symptoms reported during agitation episodes included feeling uneasy 64%, restless 63%, and nervous 63%, along with other symptoms such as feeling tense and being unable to sit still.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acute Agitation and Aggression diagnosed prevalence pool? Download report @ Acute Agitation and Aggression Treatment Market

Acute Agitation and Aggression Drugs Uptake

This section focuses on the uptake rate of the potential Acute Agitation and Aggression drugs recently launched in the Acute Agitation and Aggression market or expected to be launched in 2020-2034. The analysis covers the Acute Agitation and Aggression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acute Agitation and Aggression Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acute Agitation and Aggression market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Agitation and Aggression Pipeline Development Activities

The Acute Agitation and Aggression report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Agitation and Aggression key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acute Agitation and Aggression market share by 2034? Click here @ Acute Agitation and Aggression Drugs and Therapies

Acute Agitation and Aggression Therapeutics Assessment

Major key companies are working proactively in the Acute Agitation and Aggression Therapeutics market to develop novel therapies which will drive the Acute Agitation and Aggression treatment markets in the upcoming years are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.

Do you know how new drug market launch will be impacting the Acute Agitation and Aggression market CAGR? Download sample report @ Acute Agitation and Aggression Clinical Trials and FDA Approvals

Acute Agitation and Aggression Report Key Insights

1. Acute Agitation and Aggression Patient Population

2. Acute Agitation and Aggression Market Size and Trends

3. Key Cross Competition in the Acute Agitation and Aggression Market

4. Acute Agitation and Aggression Market Dynamics (Key Drivers and Barriers)

5. Acute Agitation and Aggression Market Opportunities

6. Acute Agitation and Aggression Therapeutic Approaches

7. Acute Agitation and Aggression Pipeline Analysis

8. Acute Agitation and Aggression Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acute Agitation and Aggression Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acute Agitation and Aggression Competitive Intelligence Analysis

4. Acute Agitation and Aggression Market Overview at a Glance

5. Acute Agitation and Aggression Disease Background and Overview

6. Acute Agitation and Aggression Patient Journey

7. Acute Agitation and Aggression Epidemiology and Patient Population

8. Acute Agitation and Aggression Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Agitation and Aggression Unmet Needs

10. Key Endpoints of Acute Agitation and Aggression Treatment

11. Acute Agitation and Aggression Marketed Products

12. Acute Agitation and Aggression Emerging Therapies

13. Acute Agitation and Aggression Seven Major Market Analysis

14. Attribute Analysis

15. Acute Agitation and Aggression Market Outlook (7 major markets)

16. Acute Agitation and Aggression Access and Reimbursement Overview

17. KOL Views on the Acute Agitation and Aggression Market

18. Acute Agitation and Aggression Market Drivers

19. Acute Agitation and Aggression Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Agitation and Aggression Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Soft tissue sarcoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Soft tissue sarcoma Market”

Leading Soft tissue sarcoma companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, more

(Albany, USA) DelveInsight’s “Soft tissue sarcoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Soft tissue sarcoma, historical and forecasted epidemiology as well as the Soft tissue sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

In 2025, ~13,520 new U.S. soft tissue sarcoma (STS) cases are expected, with common types including undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma. Diagnosis can be challenging due to subtype overlap. Current treatments for advanced STS historically rely on chemotherapy, but FDA approvals for targeted agents like AYVAKIT and TAZVERIK, alongside regorafenib and pazopanib, have expanded options. Emerging drugs such as Fibromun and INT230-6 are in late-stage trials, aiming to improve efficacy and reduce toxicity. Surgery remains critical for localized disease, with radiotherapy as adjunctive therapy. Immunotherapy, oncolytic viruses, and next-generation sequencing are shaping future strategies. The U.S. leads the STS market, followed by Germany in the EU4. Key players include Philogen, Intensity Therapeutics, Eli Lilly, and others. Uptake of new therapies will depend on competitive positioning, safety, efficacy, and regulatory approval. Expert insights highlight encouraging outcomes from novel combination therapies, indicating a promising evolution in STS management.

Request for a Free Sample Report @ Soft tissue sarcoma Market Forecast

Some facts of the Soft tissue sarcoma Market Report are:

According to DelveInsight, Soft tissue sarcoma market size is expected to grow at a decent CAGR by 2034.
In 2024, the United States accounted for the largest market size of Soft tissue sarcoma, in comparison to EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Leading Soft tissue sarcoma companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Key Soft tissue sarcoma Therapies expected to launch in the market are AL3818, L19 TNF, Camsirubicin, and others.
In July 2025, John Rieth announced a study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
In July 2025, Eli Lilly and Company conducted a study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
In July 2025, Polaris Group conducted a phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
In 2025, approximately 13,520 new cases of soft tissue sarcoma are expected to be diagnosed in the United States, including about 7,600 in males and 5,920 in females, according to the American Cancer Society.
The most common soft tissue sarcomas in adults include undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.

Soft tissue sarcoma Overview

Soft tissue sarcoma (STS) is a rare and heterogeneous group of malignant tumors that arise from the soft tissues of the body, including muscles, fat, blood vessels, nerves, tendons, and connective tissues. Accounting for less than 1% of all adult cancers, STS can develop in any part of the body but is most commonly found in the extremities, trunk, retroperitoneum, and head and neck region. There are more than 50 histological subtypes, such as liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma, each with distinct biological behavior and treatment response.

The exact cause of Soft tissue sarcoma is often unknown, but risk factors include prior radiation therapy, certain genetic syndromes (e.g., Li-Fraumeni syndrome, neurofibromatosis type 1), chronic lymphedema, and exposure to specific chemicals. Soft tissue sarcoma Symptoms vary depending on the tumor’s size and location, with painless swelling or a growing mass being common early signs.

Soft tissue sarcoma Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histopathological confirmation. Standard treatment includes surgical resection with clear margins, often combined with radiotherapy and, in certain cases, chemotherapy or targeted therapy. Despite advances, recurrence and metastasis remain challenges, emphasizing the need for ongoing research into more effective systemic treatments for Soft tissue sarcoma.

Learn more about Soft tissue sarcoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Soft tissue sarcoma Treatment Market

Soft tissue sarcoma Market Outlook

According to DelveInsight, the Soft tissue sarcoma market in 7MM is expected to witness a major change in the study period 2020-2034.

The soft tissue sarcoma (STS) market is driven by increasing disease awareness, advances in diagnostic imaging, and the development of novel targeted therapies and immunotherapies. Growing research into the molecular biology of STS has led to precision medicine approaches, enabling subtype-specific treatments such as tyrosine kinase inhibitors (e.g., pazopanib) and monoclonal antibodies. Rising incidence rates, supportive regulatory frameworks for orphan diseases, and expanding clinical trial activity further boost market growth. The entry of innovative therapies and combination regimens is improving patient outcomes, creating opportunities for pharmaceutical companies to address unmet needs in advanced and metastatic disease.

However, market growth is hindered by several barriers, including the rarity and heterogeneity of STS, which complicates diagnosis, limits large-scale clinical trial enrollment, and delays drug development. Many subtypes respond poorly to conventional chemotherapy, and treatment resistance remains a major challenge. High costs of novel therapies, coupled with limited access in low- and middle-income regions, further restrict market expansion. Additionally, the lack of reliable biomarkers for early detection and treatment monitoring poses a significant hurdle. Overall, while scientific advances and investment are fueling progress, the complex nature of STS continues to challenge both clinical management and market growth.

Soft tissue sarcoma Epidemiology

The Soft tissue sarcoma epidemiology section provides insights into the historical and current Soft tissue sarcoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Soft tissue sarcoma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total incident cases of soft tissue sarcoma
Gender-specific cases of soft tissue sarcomas
Type-specific cases of soft tissue sarcoma
Age-specific cases of soft tissue sarcoma
Stage-specific cases of soft tissue sarcoma
Extremities-specific cases of soft tissue sarcoma
Total Treated cases of soft tissue sarcoma

Explore more about Soft tissue sarcoma Epidemiology @ Soft tissue sarcoma Market Dynamics

Soft tissue sarcoma Drugs Uptake

This section focuses on the uptake rate of the potential Soft tissue sarcoma drugs recently launched in the Soft tissue sarcoma market or expected to be launched in 2025-2034. The analysis covers the Soft tissue sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Soft tissue sarcoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Soft tissue sarcoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Soft tissue sarcoma Pipeline Development Activities

The Soft tissue sarcoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Soft tissue sarcoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Soft tissue sarcoma pipeline development activities @ Soft tissue sarcoma Medication and Companies

Soft tissue sarcoma Therapeutics Assessment

Major key companies are working proactively in the Soft tissue sarcoma market to develop novel therapies which will drive the Soft tissue sarcoma treatment markets in the upcoming years are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Learn more about the emerging Soft tissue sarcoma therapies & key companies @ Soft tissue sarcoma Clinical Trials and FDA Approvals

Soft tissue sarcoma Report Key Insights

1. Soft tissue sarcoma Patient Population

2. Soft tissue sarcoma Market Size and Trends

3. Key Cross Competition in the Soft tissue sarcoma Market

4. Soft tissue sarcoma Market Dynamics (Key Drivers and Barriers)

5. Soft tissue sarcoma Market Opportunities

6. Soft tissue sarcoma Therapeutic Approaches

7. Soft tissue sarcoma Pipeline Analysis

8. Soft tissue sarcoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Soft tissue sarcoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Soft tissue sarcoma Competitive Intelligence Analysis

4. Soft tissue sarcoma Market Overview at a Glance

5. Soft tissue sarcoma Disease Background and Overview

6. Soft tissue sarcoma Patient Journey

7. Soft tissue sarcoma Epidemiology and Patient Population

8. Soft tissue sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Soft tissue sarcoma Unmet Needs

10. Key Endpoints of Soft tissue sarcoma Treatment

11. Soft tissue sarcoma Marketed Products

12. Soft tissue sarcoma Emerging Therapies

13. Soft tissue sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Soft tissue sarcoma Market Outlook (7 major markets)

16. Soft tissue sarcoma Access and Reimbursement Overview

17. KOL Views on the Soft tissue sarcoma Market

18. Soft tissue sarcoma Market Drivers

19. Soft tissue sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft tissue sarcoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Adenoid cystic carcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Adenoid cystic carcinoma Market”

Adenoid cystic carcinoma companies are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.

(Albany, USA) DelveInsight’s “Adenoid cystic carcinoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Adenoid cystic carcinoma, historical and forecasted epidemiology as well as the Adenoid cystic carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Adenoid cystic carcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adenoid cystic carcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Adenoid cystic carcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Adenoid cystic carcinoma market.

Request for a Free Sample Report @ Adenoid cystic carcinoma Market Forecast

Some facts of the Adenoid cystic carcinoma Market Report are:

According to DelveInsight, Adenoid cystic carcinoma market size is expected to grow at a decent CAGR by 2034.
Leading Adenoid cystic carcinoma companies working in the market are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.
Key Adenoid cystic carcinoma Therapies expected to launch in the market are Gotistobart (ONC-392), Alrizomadlin (APG-115), REM-422, Emi-Le (XMT-1660), RGT-61159, and many others.
In June 2025, Ascentage Pharma announced new Phase II clinical data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 61st ASCO Annual Meeting. The study evaluated alrizomadlin alone or with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma and other solid tumors.
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company’s B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois. The presentation will focus on Emi-Le’s Phase 1 dose escalation and backfill cohorts as of a March 8, 2025 data cut-off in patients with triple-negative breast cancer (TNBC); hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; ovarian cancer; endometrial cancer and adenoid cystic carcinoma type 1 (ACC-1).
At the AACR Annual Meeting 2025, Remix Therapeutics presented new preclinical data in Session PO.ET09.10 highlighting REM-422, showing potent anti-tumor activity in xenograft models of adenoid cystic carcinoma underscoring its promise as a novel therapeutic strategy.
In October 2024, Rgenta Therapeutics announced the dosing of the first patients in a Phase I trial of RGT-61159, an oral small molecule targeting RNA regulation. The drug is being developed for adenoid cystic carcinoma, colorectal cancer, acute myeloid leukemia, and other solid tumors.

Adenoid cystic carcinoma Overview

Adenoid cystic carcinoma (ACC) is a rare, typically slow-growing malignancy that most often arises in the salivary glands but can also occur in other locations such as the lacrimal glands, trachea, breast, and skin. Despite its indolent growth, ACC is notorious for its tendency to invade surrounding nerves (perineural invasion) and its high risk of late local recurrence and distant metastases, particularly to the lungs, liver, and bones.

Clinically, Adenoid cystic carcinoma often presents as a painless mass in the affected gland or organ, with symptoms depending on the tumor’s location. For example, salivary gland ACC may cause facial numbness, weakness, or difficulty swallowing if cranial nerves are involved. The disease affects both men and women, typically in middle age, though it can occur at any age.

Adenoid cystic carcinoma Diagnosis is confirmed through histopathological examination, often supported by imaging techniques such as MRI or CT scans to assess local extension and metastasis. Surgical resection remains the primary treatment, frequently combined with postoperative radiotherapy to improve local control. Chemotherapy has limited effectiveness, but targeted and immunotherapeutic approaches are under investigation.

Due to its unpredictable behavior and risk of late metastasis, Adenoid cystic carcinoma requires long-term follow-up, making early detection and comprehensive management essential for improving patient outcomes.

Do you know what will be the Adenoid cystic carcinoma market share in 7MM by 2034 @ Adenoid Cystic Carcinoma Treatment Market

Adenoid cystic carcinoma Market

Adenoid cystic carcinoma (ACC) is the third most common malignant salivary gland tumor, predominantly affecting the submandibular gland but often originating from minor salivary glands in the palate, cheeks, sinuses, tongue, and other areas. The U.S. holds the largest ACC market compared to EU4, the UK, and Japan. With no approved systemic therapies, there is a critical unmet need driving innovation from companies like Elevar Therapeutics, Remix Therapeutics, Rgenta Therapeutics, and others. Promising pipeline candidates include alrizomadlin, Gotistobart, REM-422, and RGT-61159, with recent clinical and preclinical advancements presented at major oncology conferences, reflecting growing momentum toward novel targeted treatment strategies for ACC. During the forecast period, pipeline candidates such as Alrizomadlin, Gotistobart, REM-422, RGT-61159, and others are expected to drive the rise in Adenoid cystic carcinoma market size.

The adenoid cystic carcinoma (ACC) market is driven by several factors, primarily the rising incidence of malignant salivary gland tumors and the high unmet medical need due to the lack of approved systemic therapies. The disease’s aggressive nature, characterized by perineural invasion, local recurrence, and distant metastasis, fuels the demand for more effective treatment options. Advancements in molecular biology and precision medicine have accelerated the development of targeted therapies, including RNA-targeting drugs, antibody-drug conjugates (ADCs), and immunotherapies. Increasing investment by biotech companies such as Elevar Therapeutics, Rgenta Therapeutics, Remix Therapeutics, and Ascentage Pharma, combined with supportive regulatory incentives for rare cancers, is further driving research and innovation.

However, the market faces significant barriers. Adenoid cystic carcinoma’s rarity limits patient recruitment for large-scale clinical trials, slowing drug development timelines. The tumor’s slow-growing but persistent nature makes treatment response evaluation challenging, complicating clinical endpoints. Existing therapies, such as surgery and radiotherapy, offer limited efficacy in advanced disease, and chemotherapy remains largely ineffective. High R&D costs, coupled with uncertain commercial returns for orphan indications, may deter some industry players. Additionally, the biological complexity of Adenoid cystic carcinoma, including resistance mechanisms, poses a challenge in developing durable, broadly effective treatments. These factors collectively shape both the opportunities and obstacles in the Adenoid cystic carcinoma market.

According to DelveInsight, the Adenoid cystic carcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Adenoid cystic carcinoma Epidemiology

The Adenoid cystic carcinoma epidemiology section provides insights into the historical and current Adenoid cystic carcinoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Adenoid cystic carcinoma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Incident Cases of Adenoid cystic carcinoma
Age-specific Cases of Adenoid cystic carcinoma
Gender-specific Cases of Adenoid cystic carcinoma
Site-specific Cases of Adenoid cystic carcinoma
Treated Cases of Adenoid cystic carcinoma

Interested to know how the emerging diagnostic approaches will be contributing in increased Adenoid cystic carcinoma patient pool? Download report @ Adenoid cystic carcinoma Incidence

Adenoid cystic carcinoma Drugs Uptake

This section focuses on the uptake rate of the potential Adenoid cystic carcinoma drugs recently launched in the Adenoid cystic carcinoma market or expected to be launched in 2020-2034. The analysis covers the Adenoid cystic carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Adenoid cystic carcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Adenoid cystic carcinoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adenoid cystic carcinoma Pipeline Development Activities

The Adenoid cystic carcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Adenoid cystic carcinoma key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Adenoid cystic carcinoma market share by 2034? Click here @ Adenoid cystic carcinoma Clinical Trials and FDA Approvals

Adenoid cystic carcinoma Therapeutics Assessment

Major key companies are working proactively in the Adenoid cystic carcinoma Therapeutics market to develop novel therapies which will drive the Adenoid cystic carcinoma treatment markets in the upcoming years are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.

Do you know how emerging drug launch will be impacting the Adenoid cystic carcinoma market CAGR? Download sample report @ Adenoid cystic carcinoma Drugs Market

Adenoid cystic carcinoma Report Key Insights

1. Adenoid cystic carcinoma Patient Population

2. Adenoid cystic carcinoma Market Size and Trends

3. Key Cross Competition in the Adenoid cystic carcinoma Market

4. Adenoid cystic carcinoma Market Dynamics (Key Drivers and Barriers)

5. Adenoid cystic carcinoma Market Opportunities

6. Adenoid cystic carcinoma Therapeutic Approaches

7. Adenoid cystic carcinoma Pipeline Analysis

8. Adenoid cystic carcinoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Adenoid cystic carcinoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Adenoid cystic carcinoma Competitive Intelligence Analysis

4. Adenoid cystic carcinoma Market Overview at a Glance

5. Adenoid cystic carcinoma Disease Background and Overview

6. Adenoid cystic carcinoma Patient Journey

7. Adenoid cystic carcinoma Epidemiology and Patient Population

8. Adenoid cystic carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Adenoid cystic carcinoma Unmet Needs

10. Key Endpoints of Adenoid cystic carcinoma Treatment

11. Adenoid cystic carcinoma Marketed Products

12. Adenoid cystic carcinoma Emerging Therapies

13. Adenoid cystic carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Adenoid cystic carcinoma Market Outlook (7 major markets)

16. Adenoid cystic carcinoma Access and Reimbursement Overview

17. KOL Views on the Adenoid cystic carcinoma Market

18. Adenoid cystic carcinoma Market Drivers

19. Adenoid cystic carcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adenoid cystic carcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Acoustic Neuroma Market”

Acoustic Neuroma companies are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

(Albany, USA) DelveInsight’s report, “Acoustic Neuroma Market Insights, Epidemiology, and Market Forecast–2034”, offers a comprehensive analysis of Acoustic Neuroma, including historical and projected epidemiology, along with market trends across the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report details current treatment practices, emerging therapies, market share by individual treatments, and the Acoustic Neuroma market size from 2020 to 2034, segmented across the seven major markets. It further outlines the existing treatment algorithms, key market drivers and barriers, as well as unmet medical needs—identifying the best growth opportunities and evaluating the market’s overall potential.

Request for a Free Sample Report @ Acoustic Neuroma Market Forecast

Some facts of the Acoustic Neuroma Market Report are:

According to DelveInsight, Acoustic Neuroma market size is expected to grow at a decent CAGR by 2034.
Leading Acoustic Neuroma companies working in the market are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.
Key Acoustic Neuroma Therapies expected to launch in the market are AK-antiVEGF, and many others.
In August 2025, Akouos, Inc announced results of a Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
In April 2025, Reveal Pharmaceuticals Inc announced results of a Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients
According to our finding, the overall incidence of vestibular schwannoma is approximately 3 to 5 per 100,000 person-years. The incidence rises with advancing age. For patients over 70 years of age, the incidence may be as high as 21 per 100,000 person-years.
As per Greene J et al. (2024), Schwannomas account for approximately 8% of all clinically manifested intracranial tumors. However, genetic factors contribute to developing bilateral acoustic neuromas, constituting less than 5% of all schwannomas.

Acoustic Neuroma Overview

Acoustic neuroma, also known as vestibular schwannoma, is a rare, typically benign tumor that develops from the Schwann cells covering the vestibulocochlear nerve (cranial nerve VIII), which is responsible for hearing and balance. These tumors grow slowly and are usually located between the inner ear and the brain. The condition often presents with unilateral or asymmetric hearing loss, tinnitus (ringing in the ear), dizziness, and balance disturbances. As the tumor enlarges, it can compress adjacent cranial nerves, including the trigeminal nerve, leading to facial numbness or tingling, and in severe cases, affect brainstem function.

The incidence of acoustic neuroma is estimated at 3–5 cases per 100,000 person-years, with higher prevalence among older adults, especially those over 70 years. While most cases occur sporadically, some are associated with neurofibromatosis type 2 (NF2), a genetic disorder that causes multiple tumors of the nervous system. Diagnosis is typically made through magnetic resonance imaging (MRI).

Current management strategies include active surveillance, microsurgical removal, and stereotactic radiosurgery, depending on tumor size, growth rate, symptoms, and patient health. There are currently no FDA-approved drugs for acoustic neuroma, though off-label treatments like bevacizumab show promise in selected cases, highlighting an unmet need for targeted medical therapies.

Do you know what will be the Acoustic Neuroma market share in 7MM by 2034 @ Acoustic Neuroma Treatment Market

Acoustic Neuroma Market Outlook

Between 2025 and 2034, the acoustic neuroma market is projected to grow steadily, fueled by improved diagnostics, increased awareness, and advances in treatments such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies.

The aging population and higher prevalence of NF2-associated tumors are expanding the patient base. Novel drug candidates, notably Akouos’s AK-antiVEGF, aim to control tumor growth and preserve hearing, though no FDA-approved therapies currently exist for this condition. Present treatments—surgery, radiotherapy, and active surveillance—carry notable risks, highlighting the urgent need for safer, nerve-preserving options. Off-label use of agents like bevacizumab, lapatinib, and everolimus has shown promise, particularly in NF2 patients.

Acoustic neuroma typically causes hearing loss, tinnitus, dizziness, and facial numbness, with incidence increasing with age. Despite its benign nature, the tumor can cause debilitating symptoms. The current limited pipeline emphasizes a significant unmet need, but ongoing innovations suggest a potentially transformative decade ahead for acoustic neuroma management.

The acoustic neuroma market is driven by advancements in diagnostic imaging, increasing disease awareness, and improved treatment modalities such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies. The rising prevalence of neurofibromatosis type 2 (NF2)-associated tumors, coupled with an aging global population, is expanding the patient pool. Additionally, the development of novel drug candidates like Akouos’s AK-antiVEGF, aimed at tumor control and hearing preservation, reflects growing research interest in addressing unmet needs.

However, market growth faces significant barriers, including the absence of FDA-approved drugs specifically for acoustic neuroma, a limited drug development pipeline, and the high risks associated with current treatment options such as surgery and radiotherapy. The rarity of the disease also limits large-scale clinical trials, slowing therapeutic innovation. Moreover, the benign nature of the tumor and the availability of active surveillance as a management strategy can reduce demand for aggressive interventions, creating further challenges in market expansion.

Acoustic Neuroma Epidemiology

The Acoustic Neuroma epidemiology section provides insights into the historical and current Acoustic Neuroma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acoustic Neuroma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total incident Cases of acoustic neuroma
Total Diagnosed incident Cases of acoustic neuroma
Age-specific Cases of acoustic neuroma
Gender-specific Cases of acoustic neuroma

Some of the facts:

Acoustic neuromas are estimated to affect about 1 in 100,000 people in the general population.
Acoustic neuromas affect women more often than men. Most cases of acoustic neuroma develop in individuals between the ages of 30 and 60. Although quite rare, they can develop in children.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acoustic Neuroma diagnosed prevalence pool? Download report @ Acoustic Neuroma Prevalence

Acoustic Neuroma Drugs Uptake

This section focuses on the uptake rate of the potential Acoustic Neuroma drugs recently launched in the Acoustic Neuroma market or expected to be launched in 2020-2034. The analysis covers the Acoustic Neuroma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acoustic Neuroma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acoustic Neuroma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acoustic Neuroma Pipeline Development Activities

The Acoustic Neuroma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acoustic Neuroma companies involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acoustic Neuroma market share by 2034? Click here @ Acoustic Neuroma Medication and Drugs

Acoustic Neuroma Therapeutics Assessment

Major key companies are working proactively in the Acoustic Neuroma Therapeutics market to develop novel therapies which will drive the Acoustic Neuroma treatment markets in the upcoming years are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

Do you know how emerging drug launch will be impacting the Acoustic Neuroma market CAGR? Download sample report @ Acoustic Neuroma Clinical Trials and FDA Approvals

Acoustic Neuroma Report Key Insights

1. Acoustic Neuroma Patient Population

2. Acoustic Neuroma Market Size and Trends

3. Key Cross Competition in the Acoustic Neuroma Market

4. Acoustic Neuroma Market Dynamics (Key Drivers and Barriers)

5. Acoustic Neuroma Market Opportunities

6. Acoustic Neuroma Therapeutic Approaches

7. Acoustic Neuroma Pipeline Analysis

8. Acoustic Neuroma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acoustic Neuroma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acoustic Neuroma Competitive Intelligence Analysis

4. Acoustic Neuroma Market Overview at a Glance

5. Acoustic Neuroma Disease Background and Overview

6. Acoustic Neuroma Patient Journey

7. Acoustic Neuroma Epidemiology and Patient Population

8. Acoustic Neuroma Treatment Algorithm, Current Treatment, and Medical Practices

9. Acoustic Neuroma Unmet Needs

10. Key Endpoints of Acoustic Neuroma Treatment

11. Acoustic Neuroma Marketed Products

12. Acoustic Neuroma Emerging Therapies

13. Acoustic Neuroma Seven Major Market Analysis

14. Attribute Analysis

15. Acoustic Neuroma Market Outlook (7 major markets)

16. Acoustic Neuroma Access and Reimbursement Overview

17. KOL Views on the Acoustic Neuroma Market

18. Acoustic Neuroma Market Drivers

19. Acoustic Neuroma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

“Tendonitis Pipeline Analysis”

DelveInsight’s, “Tendonitis Pipeline Insight 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendonitis pipeline landscape. It covers the Tendonitis pipeline drug profiles, including Tendonitis clinical trials and nonclinical stage products. It also covers the Tendonitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that more than four key companies are actively engaged in developing over four treatment therapies for Tendonitis.

Tendonitis Overview:

Tendonitis, also called tendinopathy, is the inflammation of a tendon — the tough connective tissue that links muscles to bones. It often develops due to injury, trauma, or repetitive joint movements. Based on the affected area, it may be referred to by specific names such as Achilles tendonitis or tennis elbow.

The condition commonly impacts the elbows, heels, shoulders, and wrists. Standard treatment includes rest, pain-relief medications, and anti-inflammatory drugs, while physical therapy helps strengthen muscles and support recovery. In more severe cases, surgical intervention may be necessary to repair the damaged tendon.

Request for a detailed insights report on Tendonitis pipeline insights @ https://www.delveinsight.com/report-store/tendonitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Tendonitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Tendonitis Therapeutics Market.

Key Takeaways from the Tendonitis Pipeline Report

DelveInsight’s Tendonitis pipeline report highlights a strong development landscape, with over four active companies working on more than four therapies for treating Tendonitis.
Key players in this space include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others, all aiming to introduce innovative drugs to enhance treatment options.
Notable pipeline candidates currently in various stages of development include SI-613, MP1032, and others.
In addition, device-based innovations are emerging — for instance, TendoNova’s Ocelot, a handheld tool for mechanically fragmenting and debriding targeted tendon tissues, received FDA 510(k) clearance in May 2022 for commercial use in conditions such as tennis elbow and plantar fasciitis. Similarly, in May 2022, CoNextions Inc. secured FDA 510(k) clearance for a device designed to improve healing and functional outcomes in tendon repair surgeries.

Tendonitis Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Tendonitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendonitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Tendonitis market.

Download our free sample page report on Tendonitis pipeline insights

Tendonitis Emerging Drugs

SI-613: Seikagaku Corporation
MP1032: MetrioPharm

Tendonitis Companies

Around four major companies are actively developing therapies for tendonitis, with Seikagaku Corporation having one of the most advanced drug candidates currently in Phase II clinical trials.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Tendonitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Tendonitis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Tendonitis Therapies and Key Companies: Tendonitis Clinical Trials and advancements

Tendonitis Pipeline Therapeutic Assessment

• Tendonitis Assessment by Product Type

• Tendonitis By Stage

• Tendonitis Assessment by Route of Administration

• Tendonitis Assessment by Molecule Type

Download Tendonitis Sample report to know in detail about the Tendonitis treatment market @ Tendonitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Tendonitis Current Treatment Patterns

4. Tendonitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Tendonitis Late-Stage Products (Phase-III)

7. Tendonitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Tendonitis Discontinued Products

13. Tendonitis Product Profiles

14. Tendonitis Key Companies

15. Tendonitis Key Products

16. Dormant and Discontinued Products

17. Tendonitis Unmet Needs

18. Tendonitis Future Perspectives

19. Tendonitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Tendonitis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

Cutaneous T-Cell Lymphoma Pipeline Drugs Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Cutaneous T-cell lymphoma Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook

Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas.
In August 2025, Prescient Therapeutics Ltd conducted a phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL).
DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.

Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

Cutaneous T-cell lymphoma Emerging Drugs

HyBryte: Soligenix

HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States.

AFM13: Affimed GmbH

AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma.

ASTX660: Otsuka Pharmaceutical Co., Ltd

ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL.

WUCART007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL.

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs

Cutaneous T-Cell Lymphoma Companies

HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T-Cell Lymphoma Pipeline Report

Coverage- Global
Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Cutaneous T-cell lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cutaneous T-cell lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
AFM13: Affimed GmbH
Early Stage Products (Phase I)
WUCART007: Wugen
Preclinical Stage Products
Drug Name: Company Name
Inactive Products
Cutaneous T-cell lymphoma Key Companies
Cutaneous T-cell lymphoma Key Products
Cutaneous T-cell lymphoma- Unmet Needs
Cutaneous T-cell lymphoma- Market Drivers and Barriers
Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
Cutaneous T-cell lymphoma Analyst Views
Cutaneous T-cell lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T-Cell Lymphoma Pipeline Drugs Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

Chronic Kidney Disease Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research. Learn more about our innovative pipeline today! @ Chronic Kidney Disease Pipeline Outlook

Key Takeaways from the Chronic Kidney Disease Pipeline Report

In August 2025, Boehringer Ingelheim announced a study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease.
In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR.
DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments. Download for updates and be a part of the revolution in care @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Emerging Drugs Profile

Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.

Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Chronic Kidney Disease Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chronic Kidney Disease Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

Coverage- Global
Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Chronic Kidney Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Kidney Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Baxdrostat: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BI-685509: Boehringer Ingelheim
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RGLS8429: Regulus Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chronic Kidney Disease Key Companies
Chronic Kidney Disease Key Products
Chronic Kidney Disease- Unmet Needs
Chronic Kidney Disease- Market Drivers and Barriers
Chronic Kidney Disease- Future Perspectives and Conclusion
Chronic Kidney Disease Analyst Views
Chronic Kidney Disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

Atopic Dermatitis Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Atopic Dermatitis Pipeline Outlook Report

Key Takeaways from the Atopic Dermatitis Pipeline Report

In August 2025, Alphyn Biologics announced a study aiming to enroll 72 participants across 10 sites in Australia. There are 2 cohorts: Cohort 1: Mild to moderate atopic dermatitis Cohort 2: Mild to moderate atopic dermatitis – with secondary skin infection. Once assigned to a cohort participants will be randomised into 1 of 2 Groups: Arm A: Zabalafin hydrogel or Arm B: vehicle (placebo). Randomisation will be 2:1 ratio. There is up to 2 weeks for screening and study treatment period of 16 weeks.
In August 2025, Incyte Corporation announced a study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to
In August 2025, Inmagene LLC conducted a study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 120-+ pipeline therapies for Atopic Dermatitis treatment.
The leading Atopic Dermatitis Companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Promising Atopic Dermatitis Pipeline Therapies such as Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.

Learn how leading Atopic Dermatitis Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Atopic Dermatitis Clinical Trials Assessment

Atopic Dermatitis Emerging Drugs

ICP-332: Innocare Pharma

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.

APG777: Apogee Therapeutics

APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

STAR-0310: Astria Therapeutics

STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.

The Atopic Dermatitis Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

From early-stage research to late-phase Atopic Dermatitis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Atopic Dermatitis Treatment Drugs

Atopic Dermatitis Companies

Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest Atopic Dermatitis Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives

Scope of the Atopic Dermatitis Pipeline Report

Coverage- Global
Atopic Dermatitis Companies- Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Atopic Dermatitis Pipeline Therapies- Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Atopic Dermatitis Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Atopic Dermatitis Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Atopic Dermatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Dermatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ICP-332: Innocare Pharma
Mid Stage Products (Phase II)
APG777: Apogee Therapeutics
Early Stage Products (Phase I)
STAR-0310: Astria Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Atopic Dermatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

Microbiome Disease Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Microbiome Disease Pipeline Insights 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Microbiome Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Microbiome Disease Pipeline Outlook Report

Key Takeaways from the Microbiome Disease Pipeline Report

In July 2025, Microbiome Health Sciences announced a study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 adjunctive to PPI therapy on heartburn-free days in subjects with GERD-related heartburn symptoms who self-report improvement while on sustained daily PPI therapy. Heartburn-free days will be determined by subject report specific to any of the three questions (“burning feeling behind the breastbone” and/or “pain behind your breastbone” and/or “heartburn”; Questions 1, 2 & 3 of the RESQ-eD).
DelveInsight’s Microbiome Disease pipeline report depicts a robust space with 140+ active players working to develop 180+ pipeline therapies for Microbiome Disease treatment.
The leading Microbiome Disease Companies such as MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.
Promising Microbiome Disease Pipeline Therapies such as Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide, and others.

Learn how leading Microbiome Disease Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Microbiome Disease Clinical Trials Assessment

Microbiome Disease Emerging Drugs Profile

MaaT 013: MaaT Pharma

MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites). It aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 is an off-the-shelf, healthy-multi-donors-derived product intended for acute, hospital use. Currently the drug is in Phase III stage of development for the treatment of Graft-versus-host disease.

QBKPN: Qu Biologics

QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs. The clinical trial is designed to assess QBKPN’s effectiveness in restoring innate immunity, the prevention of serious morbidity and mortality from respiratory infections, including COVID-19 and its variants, and reduction in all-cause mortality. QBKPN SSI is designed to restore and enhance innate immune function, the body’s first line of defense against all infections and other diseases such as cancer. Currently the drug is in Phase II stage of development for the treatment of immunodeficiency disorders.

BMC128: Biomica Ltd.

BMC128 is a rationally-designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene’s MicroBoost AI platform. Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbour specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes. Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host’s microbial community with individually selected, cultured bacteria. The drug is currently in Phase I stage of development for the treatment of patients with colorectal cancer.

SER-155: Seres Therapeutics

SER-155 is a consortium of bacterial species selected using Seres’ reverse translation discovery and development MbTx platform technologies. The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays, and in vivo disease models. The SER-155 composition is designed to prevent and decrease the colonization and abundance of bacterial pathogens that can harbor antibiotic resistance and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infections and GvHD. SER-155 has received FDA Fast Track Designation. The drug is currently in Phase I stage of development for the treatment of patients with Bacteraemia.

MVT-201: Micro Viable Therapeutics

MVT-201, is an orally administered capsule generated under cGMP conditions representing the complete gut microbiota of a clinically validated healthy donor and will get into the clinical trials in 2024 for undisclosed targets. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is a unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding. This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount. The drug is currently in Preclinical stage of development for the treatment of patients with infectious diseases.

The Microbiome Disease Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Microbiome Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microbiome Disease Treatment.
Microbiome Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Microbiome Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Microbiome Disease market.

From early-stage research to late-phase Microbiome Disease Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Microbiome Disease Treatment Drugs

Microbiome Disease Companies

MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.

Microbiome Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Microbiome Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Stay updated with the latest Microbiome Disease Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Microbiome Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Microbiome Disease Pipeline Report

Coverage- Global
Microbiome Disease Companies- MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.
Microbiome Disease Pipeline Therapies- Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide, and others.
Microbiome Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Microbiome Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Microbiome Disease Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Microbiome Disease Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Microbiome Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Microbiome Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
MaaT 013: MaaT Pharma
Mid Stage Products (Phase II)
QBKPN: Qu Biologics
Early Stage Products (Phase I)
BMC128: Biomica Ltd.
Preclinical and Discovery Stage Products
MVT-201: Micro Viable Therapeutics
Inactive Products
Microbiome Disease Key Companies
Microbiome Disease Key Products
Microbiome Disease- Unmet Needs
Microbiome Disease- Market Drivers and Barriers
Microbiome Disease- Future Perspectives and Conclusion
Microbiome Disease Analyst Views
Microbiome Disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microbiome Disease Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report

Key Takeaways from the ESCLC Pipeline Report

In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
DelveInsight’s ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment.
The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.

Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ ESCLC Clinical Trials Assessment

ESCLC Emerging Drugs Profile

Serplulimab+Chemo: Shanghai Henlius Biotech

Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.

Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

RYZ101: RayzeBio, Inc.

RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).

The ESCLC Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market.

From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ ESCLC Treatment Drugs

ESCLC Companies

Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.

Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

ESCLC Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest ESCLC Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives

Scope of the ESCLC Pipeline Report

Coverage- Global
ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ ESCLC Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Serplulimab+Chemo: Shanghai Henlius Biotech
Mid-Stage Products (Phase II)
Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Early Stage Products (Phase I)
RYZ101: RayzeBio, Inc.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape